Patent · US Active

Crystalline form of LNP023

US11603363B2 · kind B2 · utility

2Cited by

0References

23Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Zichen JIA · Basel, CH
Philipp Lustenberger · Warthausen, DE
Marie-Claude Meyer · Paris, FR
Massimo Moratto · Basel, CH

Key dates

Filing date	May 17, 2021
Grant date	Mar 14, 2023
Priority date	—
Expiry date	May 25, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.